메뉴 건너뛰기




Volumn 92, Issue 2, 2012, Pages 262-264

Raising orphans: How clinical development programs of drugs for rare and common diseases are different

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; NONORPHAN DRUG; ORPHAN DRUG; UNCLASSIFIED DRUG; VACCINE;

EID: 84864133268     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.87     Document Type: Article
Times cited : (22)

References (4)
  • 2
    • 84864123454 scopus 로고    scopus 로고
    • Quantum of effectiveness evidence in FDA's approval of orphan drugs DIA: National Organization for Rare Disorders (NORD)
    • Washington, DC, 11-13 October 2011
    • S asinowski, F.J. Quantum of effectiveness evidence in FDA's approval of orphan drugs DIA: National Organization for Rare Disorders (NORD). US Conference on Rare Diseases and Orphan Products (2011). Washington, DC, 11-13 October 2011.
    • (2011) US Conference on Rare Diseases and Orphan Products
    • Sasinowski, F.J.1
  • 3
    • 79958036418 scopus 로고    scopus 로고
    • Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer
    • Kesselheim, A.S., Myers, J.A. & Avorn, J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 305, 2320-2326 (2011).
    • (2011) JAMA , vol.305 , pp. 2320-2326
    • Kesselheim, A.S.1    Myers, J.A.2    Avorn, J.3
  • 4
    • 84864123449 scopus 로고    scopus 로고
    • Tufts Center For The Study Of Drug Development
    • Tufts Center for the Study of Drug Development. Approved Products Database and Orphan Products Database 〈http://csdd.tufts.edu/research/ databases〉 (2012).
    • (2012) Approved Products Database and Orphan Products Database


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.